Source: https://www.bankofengland.co.uk/-/media/boe/files/prudential-regulation/policy-statement/2026/january/ps126app1.pdf · captured 2026-09-29 · checked 2026-09-29 · c75b8196
20915 This document is effective from 1 January 2027 to accompany PS1/26.
20916Please see: www.bankofengland.co.uk/prudential-regulation/publication/2026/january/implementation-of-basel-3-1-final-rules-policy-statement.
20919 1 APPLICATION AND DEFINITIONS
20921 1.1 Unless otherwise stated, this Part applies to:
20922 (1) a firm that is a CRR firm; and
20924 (2) a CRR consolidation entity.
20926 1.2 In this Part, the following definitions shall apply:
20928 means the sum of regulatory CVA for all covered transactions.
20930 has the definition in Counterparty Credit Risk (CRR) Part 1.3.
20932 has the definition in Counterparty Credit Risk (CRR) Part 1.3.
20933 commodity delta risk factor
20934 means the risk factor set in accordance with 5.30(3).
20935 commodity vega risk factor
20936 means the risk factor set in accordance with 5.30(4).
20937 counterparty credit spread risk delta risk factor
20938 means the risk factor set in accordance with 5.27(3).
20939 covered transaction
20941 (1) a derivative transaction, but excluding:
20942 (a) derivatives transacted directly with a qualifying central counterparty;
20943 (b) derivatives transacted with a clearing member, where either:
20944 (i) the clearing member acts as financial intermediary between the firm
20945 and the qualifying central counterparty; or
20946 (ii) the clearing member guarantees the performance of the firm’s
20947 exposure to the qualifying central counterparty;
20948 (c) derivatives transacted with a qualifying central counterparty where the firm is
20949 a clearing member acting as a financial intermediary between a client and the
20950 qualifying central counterparty;
20951 (d) derivatives transacted with a client, where the firm is a clearing member
20952 acting as financial intermediary between the client and the qualifying central
20954 (e) transactions giving rise to exposures with counterparties meeting the
20956 (2) a securities financing transaction, if:
20957 (a) it is fair-valued by the firm under the firm’s applicable accounting framework;
20959 (b) the firm's CVA risk arising from the transaction is material.